2023 is a key year for CGeneTech to carry forward the past and open up the future. The first domestic terfluramide, which has been put on the market, will promote the implementation of medical insurance throughout the country as soon as possible to benefit the rare patients with multiple sclerosis in China.
At the beginning of the year, the listing application of Cetagliptin, a new DPP-4 inhibitor, has been accepted by the State Food and Drug Administration. This drug is expected to become the best hypoglycemic drug in the class. The company will make good preparations for its listing and live up to the high expectations of the industry.
At the same time, the company will also complete the Pre-IPO round of financing in order to smoothly enter the capital market and continue to promote the company's continuous innovation with sufficient funds.

Now let's listen to Dr. Yu Qiang, founder and CEO of CGeneTech, through the lens of "Magic Cube of Medicine", review the "how many storms" in 2022, and wait for the new year to "blossom on the street".